Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Expertise in Nasal Delivery

3D Nasal Cast Model

preview
next
September 17, 2019
Satsuma Pharmaceuticals, Inc. (“Satsuma”) located in California, USA, was established in 2016 licensing in nasal delivery technology originally developed by Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”). Satsuma was listed on the NASDAQ Stock Market on September 13, 2019. Satsuma is developing a nasal migraine drug, STS101 (dihydroergotamine). In the Phase I clinical study, STS101 achieved high absorption that was rapid and consistent using SNBL’s nasal delivery platform. Satsuma...
August 23, 2019
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose to globally expand the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. On August 22, 2019, Satsuma announced the completion of administration to the first patient in a Phase 3 EMERGE efficacy trial of...
April 25, 2019
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose to globally expand the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. On April 24, 2019, Satsuma announced a $62 million Series-B preferred stock financing led by Wellington Management Company with...
February 21, 2019
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose to globally expand the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) using SNBL’s novel nasal delivery technology. Satsuma subsequently obtained funding from third party venture capital firms and conducted a Phase I clinical trial for its nasal dihydroergotamine formulation (“DHE”), STS101....
June 19, 2018
SNBL will be exhibiting a booth showcasing our proprietary nasal delivery technology, feasibility study program, and the application of Nose-to-Brain technology at the World Congress of Basic and Clinical Pharmacology in Kyoto (WCP2018) – July 02-05, 2018. Location: Kyoto International Conference Center Kyoto (ICC Kyoto, Takaragaike, Sakyo-ku, Kyoto 606-0001, Japan)
June 15, 2018
SNBL will present new data for our proprietary nasal delivery technology as applied to Nose-to-Brain and systemic delivery. The following posters will be presented at the Controlled Release Society (CRS) Annual Meeting in New York, NY – July 22-24, 2018: In Vitro/in Vivo Evaluations Of Nose-to-Brain Drug Delivery Platform Technology In Monkeys (Yusuke Torikai, poster number: 574) Pharmacokinetic Analysis of Absorption Characteristics of a Novel Nasal Zolmitriptan Powder Formulation in Monkeys...
April 02, 2018
Shin Nippon Biomedical Laboratories (SNBL) launches a redesigned website for their nasal delivery system as part of the Translational Research (TR) Division. The new URL for the TR website has been changed. If you have already bookmarked our website, please change your bookmark to the new address below: Old: http://www.snbl-nds.co.jp/en/ New: http://www.snbl-nds.com/ The key points of the redesigned site are as follows: 1) Updated information for novel technology application based on...
December 19, 2016
Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"; CEO: Ryoichi Nagata; Tokyo, Japan) announces that third-party allocation of new shares have been concluded for Satsuma Pharmaceuticals, Inc. ("Satsuma"; President & CEO: John Kollins; California), which was established in the US to develop migraine therapeutics. The $12M financing was co-led by RA Capital Management, LLC ("RA Capital") and TPG Biotechnology Partners V, L.P. ("TPG"). Satsuma was established in June 2016, with the purpose to...
June 08, 2015
We are pleased to announce that official homepage of TR Company of SNBL, Ltd. was renewed. Our nasal delivery platform technology is widely applicable to small molecules, peptides and vaccines. The renewed homepage has been updated with information assessing the applicability of nasal delivery platform technology to potential compounds. We look forward to receiving your inquiry.
June 05, 2015
BIO One-on-One Partnering at the 2015 BIO International Convention is the largest venue for private company-to-company meeting in the world. In order to create new business opportunities utilizing SNBL's nasal platform technology, we look forward to meeting you at the BIO one-on-one meeting. Meeting request at BIO One-on-One Partnering: https://app.partnering.bio.org/BIO2015

Show more